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Results: The BNP blood levels were positively correlated significantly
with E/E’ ratio (p < 0.02). Patients with elevated LV end diastolic pressure
(LVEDP), defined as E/E’ > 15 (n = 27) had highest BNP (302±68 pg/ml)
levels. E/E’ 10 to 15 group (n = 24) had a mean BNP level of 136.4±27 pg/ml,
and those with E/E’ < 10 (n = 29) had 82±20 pg/ml. A BNP value of 107.8 pg/ml
had a sensitivity of 89%, a specificity of 61% for predicting E/E’ >15. The
area under the ROC curve for BNP to detect any diastolic dysfunction was
0.757. A BNP value of 72.7 pg/ml had a sensitivity of 82.2% and a specificity
of 66.7% for detecting a diastolic dysfunction. 
Conclusions: A rapid assay for BNP can detect the presence of diastolic
abnormalities on echocardiography. In patients with preserved systolic func-
tion post myocardial infarction, elevated BNP levels might help to reinforce
the diagnosis of LV diastolic dysfunction.
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Background: Our aim was to examine the hypothesis that the sequential
use of the Verigene® rapid CYP2C19 test for genetic profiling and the Veri-
fynowTM bedside test for platelet function measurement in ACS patients may
improve P2Y12 inhibition. 
Methods and results: “Rapid” (CYP2C19*1/*1 or CYP2C19*17 carriers,
n=211) and “slow” metabolizers (CYP2C19*2 carriers, n=58) were first put
on clopidogrel and prasugrel MD for ≥2 weeks, respectively. Patients with
low inhibition >80% on prasugrel or high inhibition <30% on clopidogrel
were then switched to clopidogrel and prasugrel, respectively. Our objectives
were to demonstrate that the proportion of “rapid” metabolizers on 75mg MD
of clopidogrel within 30%-80% of P2Y12 inhibition is non-inferior to “slow”
metabolizers on prasugrel 10mg MD and (ii) to evaluate the same end-point
after switching drugs. The proportion of “rapid” and “slow” metabolizers
within 30%-80% of P2Y12 inhibition was 58.5% and 44.8%, respectively, an
absolute difference of +13.6% (95% CI (confidence interval), –0.8% to
28.1%) with a non-inferiority margin greater than the predefined margin of
–10%. Among patients out of target, all but one “slow” metabolizers displayed
low-on prasugrel platelet reactivity while the majority of “rapid” metabolizers
(70%) displayed high-on clopidogrel platelet reactivity. After switching, the
proportion of patients within 30%-80% of P2Y12 inhibition was 74.4% and
65.5% in “rapid” and “slow” metabolizers, respectively (+8.9%, 95% CI –4.7%
to 22.5%).
Conclusions: This study demonstrates a loose relationship between geno-
type and platelet function phenotype approaches but that they are complemen-
tary to select prasugrel or clopidogrel MD in stented ACS patients. 
Abstract 0109 – Table: Patients' baseline characteristics
Patients’baseline characteristics
BMS (n=30) DES (n=300) p
Sex, M/F 30/0 30/0 1
Age, y 52,03±6,35 50,2±8,45 0,34
Body mass index*, kg/m2 25,79±2,56 25,00±2,97 0,28
Hypertension, % 16,66 1,66 1
Dyslipidemia, % 33,33 33,33 1
Diabetes mellitus, % 0 0 1
Family history, % 26,66 6,66 0,07
Cigarette smoking, % 73,33 60 0,41
Previous CAD, Stroke, PAOD, % 0 0 1
Indication of coronary 
angiography
AMI (STEMI/NSTEMI, % 86,66 76,66 0,5
UA, % 13,33 16,66 1
SCAD, % 0 6,66 0,49
Time interval between PCI and 
blood sampling, d
39,16±7,68 38,73±6,76 0,81
Stent length, mm 16,3±4,24 17,56±5,71 0,33
LVEF, % 58,66±7,30 61,13±6,18 0,16
Drug therapies*
Statin, % 100 100 1
ASA, % 100 100 1
Second anti-platelet drug
Clopidogrel, % 46,66 43,33 1
Prasugrel, % 53,33 50 1
Ticagrelor, % 0 6,66 0,49
β-blocker, % 85,71 (n=28) 60 (n=25) 0,059
ACE inhibitor, % 89,28 (n=28) 80,76 (n=26) 0,46
AT-RB, % 0 (n=28) 0 (n=26) 1
OAC, % 0 0 1
Blood tests*
LDL cholesterol, g/L 0,75±0,18 0,68±0,19 0,19
HDL cholesterol, g/L 0,39±0,10 0,43±0,11 0,19
Triglyceride, g/L 0,96±0,32 0,93±0,29 0,72
Hemoblogin, g/dl 14,34±0,97 14,4±0,83 0,82
Platelets, G/L 242,93±55,90 239,56±49,61 0,8
Serum creatinine, μmol/L 88,6±14,60 82,73±14,59 0,12
CRP, mg/L 2,07±2,02 1,39±1,30 0,12
Fasted glycaemia, g/L 0,97±0,11 1,01±0,09 0,14
HbA1c, % 5,74±0,39 5,73±0,40 0,92
Continuous variables are presented as sample mean and standard deviation. 
P-values reflect comparisons between patients with a BMS and patients with 
DES and are derived from Student’s t-tests for continuous variables whereas 
qualitative data were compared with Fisher’s exact test.
The characteristics marked with an asterisk were collected on the same day 
that blood was sampled (one month after PCI).
